You are here: Industry Insights > Endometrial Cancer

News List

Higher Coffee Consumption Tied to Lower Risk for Endometrial Cancer drugs.com
January 28, 2022
Increased coffee intake is associated with a lower risk for endometrial cancer (EC), according...
Japan approves Keytruda plus Lenvima combination for endometrial cancer treatment drugs
December 28, 2021
the Ministry of Health, Labour and Welfare (MHLW) of Japan has approved Keytruda plus Lenvima combination to treat endometrial carcinoma.
EC grants approval for Merck-Eisai’s combo therapy for endometrial cancer Pharmaceutical-Technology
December 01, 2021
The European Commission (EC) has granted approval for Merck (MSD) and Eisai’s Keytruda (pembrolizumab) in combination with Lenvima (lenvatinib) to treat adults with advanced or recurrent endometrial cancer.
GSK’s PD-1 inhibitor Jemperli approved in the UK pharmatimes
June 08, 2021
GlaxoSmithKline’s (GSK) PD-1 inhibitor Jemperli has been authorised by the UK Medicines and Healthcare products Regulatory Agency (MHRA) for the treatment of recurrent or advanced endometrial cancer.
Antengene Announces IND Approval in China for a Global Phase III Trial of Selinexor in Advanced or Recurrent Endometrial Cancer prnasia
May 13, 2021
Antengene Corporation Limited, a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in-class therapeutics in hematology and oncology, today announced that China's ...
FDA approves GSK’s Jemperli for endometrial cancer pharmaceutical-technology
April 26, 2021
The US Food and Drug Administration (FDA) has approved GlaxoSmithKline’s (GSK) programmed death receptor-1 (PD-1) blocking antibody Jemperli (dostarlimab-gxly) based on its Biologics License Application (BLA) for endometrial cancer.
Antengene Announces Submission of IND Application in China for a Global Phase 3 Trial of ATG-010 (Selinexor) in Advanced or Recurrent Endometrial Cancer prnasia
January 05, 2021
Antengene Corporation Limited announced that it submitted an Investigational New Drug (IND) application to the National Medical Products Administration (NMPA) for ATG-010 (selinexor) in the treatment of Endometrial Cancer.
Oral contraceptive pills protect against ovarian and endometrial cancer, study finds europeanpharmaceuticalreview
December 22, 2020
A study has shown that the use of oral contraceptives gave women a much lower risk of developing both ovarian and endometrial cancer.
Byondis Initiates Phase II Study of Antibody-Drug Conjugate [Vic-]Trastuzumab Duocarmazine in Advanced Endometrial Cancer b3cnewswire
July 28, 2020
Byondis B.V. (formerly Synthon Biopharmaceuticals B.V.) today announced that the first patients have started treatment in its Phase II study evaluating the safety and efficacy of its investigational antibody-drug conjugate (ADC) [vic-]trastuzumab duocarma
Is Your State a Hotspot for Obesity-Linked Cancers? drugs
December 28, 2018
What state you call home may have a great deal to do with your chances of developing an obesity-related cancer, a new report suggests.....